Cyclooxygenase-2 Inhibition Sensitizes Human Colon Carcinoma Cells to TRAIL-Induced Apoptosis through Clustering of DR5 and Concentrating Death-Inducing Signaling Complex Components into Ceramide-Enriched Caveolae
- 15 December 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (24) , 11447-11458
- https://doi.org/10.1158/0008-5472.can-05-1494
Abstract
Cyclooxygenase-2 (COX-2) is up-regulated in human colon carcinomas, and its inhibition is associated with a reduction in tumorigenesis and a promotion of apoptosis. However, the mechanisms responsible for the antitumor effects of COX-2 inhibitors and how COX-2 modulates apoptotic signaling have not been clearly defined. We have shown that COX-2 inhibition sensitizes human colon carcinoma cells to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–induced apoptosis by inducing clustering of the TRAIL receptor DR5 at the cell surface and the redistribution of the death-inducing signaling complex components (DR5, FADD, and procaspase-8) into cholesterol-rich and ceramide-rich domains known as caveolae. This process requires the accumulation of arachidonic acid and sequential activation of acid sphingomyelinase for the generation of ceramide within the plasma membrane outer leaflet. The current study highlights a novel mechanism to circumvent colorectal carcinoma cell resistance to TRAIL-mediated apoptosis using COX-2 inhibitors to manipulate the lipid metabolism within the plasma membrane. (Cancer Res 2005; 65(24): 11447-58)Keywords
This publication has 39 references indexed in Scilit:
- Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibitionOncogene, 2003
- Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell linesBritish Journal of Cancer, 2003
- Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II studyInternational Journal of Cancer, 2003
- Molecular Mechanisms of Ceramide-Mediated CD95 ClusteringBiochemical and Biophysical Research Communications, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Fas/CD95/Apo-I activates the acidic sphingomyelinase via CaspasesCell Death & Differentiation, 1998
- Association of p75 with Caveolin and Localization of Neurotrophin-induced Sphingomyelin Hydrolysis to CaveolaeJournal of Biological Chemistry, 1997
- Compartmentalized Production of Ceramide at the Cell SurfacePublished by Elsevier ,1995
- Intracellular transport and metabolism of sphingomyelinBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991